DGTR opens anti-dumping probe into azepine intermediates ISBCC, 10 MISB, IDB from China
DGTR published its initiation in Case No. AD(OI) -14 /2026 on March 20, 2026. DGTR initiates an anti-dumping investigation into ISBCC, 10 MISB and their precursor IDB from China, intermediates for APIs such as carbamazepine. It covers Certain azepine intermediates, viz. ISBCC and 10 MISB and their precursor, IDB from China.
The Directorate General of Trade Remedies has initiated an anti-dumping investigation concerning imports of "Certain azepine intermediates, viz. ISBCC and 10 MISB and their precursor, IDB" originating in or exported from China, by notification dated March 20, 2026 (Case No. AD(OI)-14/2026).
The application was filed by M/s Aether Industries Limited, the sole domestic producer of IDB, which began commercial production of the subject goods in 2022–23. It alleges dumped imports causing material injury and has asked for anti-dumping duties and interim duties. The product covers IDB, ISBCC and 10 MISB, intermediates used to make anticonvulsant and antipsychotic APIs such as carbamazepine and oxcarbazepine, imported under several Chapter 29 tariff items that are indicative only.
The period of investigation is October 2024 to September 2025, and the injury period covers 2022-23, 2023-24, 2024-25 and the period of investigation. For initiation, normal value was based on the price payable in India, and the comparison with DG System export prices shows, prima facie, a significant dumping margin above de minimis. The applicant reports falling landed prices, price depression and declining profits and return on investment.
The Authority will determine the existence, degree and effect of dumping and recommend any duty needed to remove injury. Interested parties are to respond on the SETU portal within 37 days and may comment on the product scope, PCNs and injury methodology.
- Measure
- Anti-dumping
- Stage
- Initiation
- Case number
- Case No. AD(OI) -14 /2026
- File number
- F. No.6/15/2026-DGTR
- Dated
- March 20, 2026
- Published in the Gazette
- March 20, 2026
- Put online
- March 24, 2026
- Gazette ID
- CG-DL-E-24032026-271231
- Product
- Certain azepine intermediates, viz. ISBCC and 10 MISB and their precursor, IDB
- What it covers
- ISBCC (Iminostilbene Carbonyl Chloride, CAS 33948-22-0), 10 MISB (10-Methoxyiminostilbene, CAS 4698-11-7) and their precursor IDB (Iminodibenzyl, CAS 494-19-9), chemical compounds sharing the azepine ring system and used as intermediates in the synthesis of APIs, particularly anticonvulsant and antipsychotic medications such as carbamazepine and oxcarbazepine. The applicant treats the three as one product with a separate PCN for each. The product has no dedicated customs classification, and the codes named are indicative only and not binding on the scope.
- Customs codes
- 2921 30 90, 2922 19 90, 2931 90 90, 2933 19 20, 2933 99 10, 2933 99 90, 2934 99 90
- Countries
- China
- Applicant
- M/s Aether Industries Limited
- Period of investigation
- October 2024 to September 2025 (12 months)
- Injury period
- 2022 - 2023, 2023 - 2024, 2024 - 2025 and the POI
- Findings
- The applicant is the sole domestic producer of IDB in India and began commercial production of the subject goods in 2022–23; the Authority notes that it constitutes the domestic industry under Rule 2(b) and meets the standing criteria of Rule 5(3).
- Because India and China are stated to be the only producing countries, normal value for China was determined for initiation on the basis of price paid or payable in India, with reasonable adjustments for SGA expenses and profit; export price was taken from DG System CIF data, adjusted to ex-factory level.
- The comparison at ex-factory level shows, prima facie, a dumping margin above the de minimis level and significant.
- Subject import volumes were significant throughout the injury period, declined in 2023-24 after the applicant began production and increased thereafter; the applicant claims a steep decline in landed prices without a matching decline in cost of production, price depression, and deterioration in cash profit, profits and return on investment, with average inventory substantially increased.
- The Authority notes that the information provided by the applicant, prima facie, shows injury being caused to the domestic industry due to dumped imports.
- The applicant presented injury data both by adding IDB, ISBCC and 10 MISB volumes and in IDB equivalents; interested parties may comment on the injury methodology, which is to be examined during the investigation.
- Recommendation
- The Authority initiates an anti-dumping investigation under Section 9A of the Act read with Rule 5 of the Rules to determine the existence, degree and effect of the alleged dumping and to recommend the anti-dumping duty adequate to remove injury to the domestic industry. The applicant has also sought interim duties.
- Time limits
- Comments on the product under consideration and proposals for construction of PCNs: within 15 days from the date of initiation of this investigation, running concurrently with the main time limit
- Interested parties to upload confidential and non-confidential submissions on the SETU portal under Case ID AD (OI) (14/2026): within 37 days from the date on which the non-confidential version of the application would be circulated by the Authority or transmitted to the appropriate diplomatic representative of the exporting country, as per Rule 6(4) of the Rules, 1995
- Comments on issues of confidentiality: within 7 days from the date of circulation of the non-confidential version of the documents
- Requests for extension of time: at least one day before the original deadline
The notification (PDF, 865 KB)
Gazette of India, CG-DL-E-24032026-271231, published March 20, 2026.
Checked against the official copy on October 20, 2026.